Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01832350
Recruitment Status : Terminated (Sponsor decided to stop study early)
First Posted : April 16, 2013
Last Update Posted : October 29, 2019
Sponsor:
Collaborator:
Avanir Pharmaceuticals
Information provided by (Responsible Party):
St. Joseph's Hospital and Medical Center, Phoenix

Brief Summary:
The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability Scale and PLACS), with satisfactory safety and high tolerability in patients with Alzheimer's Disease (AD). The primary objective will be evaluated using a study endpoint at 1, 13, 26 weeks after initiation of treatment. The secondary objective of this study is to evaluate the benefit of treatment with Nuedexta (20/10) on cognition and functionality as demonstrated in the Rey Auditory Verbal Learning Test (RAVLT), Trail making A and B, Wechsler Memory Scale (WMS) logical memory and delayed recall, Controlled Oral Word Association (COWA), Clinical Dementia Rating (CDR), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCSADL) and the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Pseudobulbar Affect (PBA) Drug: Nuedexta (20/10) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 34 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease
Actual Study Start Date : August 28, 2012
Actual Primary Completion Date : December 1, 2015
Actual Study Completion Date : December 1, 2016


Arm Intervention/treatment
Experimental: Nuedexta (20/10)
Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
Drug: Nuedexta (20/10)
Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
Other Name: Dextromethorphan/Quinidine




Primary Outcome Measures :
  1. reduction of PBA frequency [ Time Frame: 1, 13, and 26 weeks after initiation of treatment ]

Secondary Outcome Measures :
  1. reduction of PBA severity [ Time Frame: 1, 13, and 26 weeks after initiation of treatment ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male/female 55 to 90 years, inclusive.
  • Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD.
  • Modified Hachinski Ischemia Scale score of ≤4.
  • Folstein Mini Mental State Exam score 16-26 at Visit 1.
  • Geriatric Depression Scale score ≤6. For patient with history of depression, he/she have been on steady dose of anti-depressant for at least 3 months.
  • Clinical history and relevant symptoms of Pseudobulbar Affect.
  • Center for Neurologic Study-Lability Scale score at baseline ≥13.
  • Stable hematologic, hepatic, and renal function, with no clinically significant symptoms, and with clinical laboratory results (CBC, clinical chemistry, and urinalysis) up to 1-fold higher than upper limit of normal range.
  • Resting respiratory rate 12-20/minute.
  • MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD.
  • ECG (within 4 weeks prior to entry)with no evidence of clinically significant abnormalities.
  • Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed; must be on stable dose at least 2 months before screening. Dosing must remain stable throughout the study.
  • Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must remain unchanged during course of study.
  • No current symptoms of depressive disorder.
  • Score of 19 or lower in the Beck Depression Inventory.
  • Agrees to use no prohibited medications during study.

Exclusion Criteria:

  • Has current serious or unstable illnesses that, in investigator's opinion, could interfere with analysis of safety and efficacy data; has life expectancy <2 years.
  • No reliable caregiver in frequent contact with patient (at least 10 hours/week.
  • Current or prior history of major psychiatric disturbance.
  • Have been in other clinical study within 30 days of entry.
  • Score of 20 or higher in Beck Depression Inventory.
  • Multiple episodes of head trauma, history within last year of serious infectious disease affecting the brain, head trauma resulting in protracted loss of consciousness, or myasthenia gravis.
  • Within the last 5 years, history of a primary or recurrent malignant disease.
  • Known sensitivity to quinidine or dextromethorphan.
  • History of human immunodeficiency virus, multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions.
  • History of chronic alcohol or drug abuse/dependence within the past 5 years.
  • Judged by investigator to be at serious risk for suicide.
  • Has a recent or current lab result indicating clinically significant lab abnormality.
  • At Visit 1 has ALT/SGPT values ≥2 times upper limit of normal (ULN); AST/SGOT values ≥3 times the ULN; total bilirubin values ≥2 times the ULN.
  • Resting diurnal oxygen saturation <95%.
  • Received dextromethorphan and quinidine within previous 6 months.
  • Hypotension (systolic BP <100 mm Hg); postural syncope; unexplained syncope.
  • Used medications that affect the CNS (except for AD) for less than 4 weeks.
  • On disallowed concomitant medications.
  • Experiencing acute exacerbation of underlying neurological disorder within previous 2 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01832350


Locations
Layout table for location information
United States, Arizona
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
Sponsors and Collaborators
St. Joseph's Hospital and Medical Center, Phoenix
Avanir Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Jiong Shi, MD, PhD Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ
Publications:

Layout table for additonal information
Responsible Party: St. Joseph's Hospital and Medical Center, Phoenix
ClinicalTrials.gov Identifier: NCT01832350    
Other Study ID Numbers: AVP923
First Posted: April 16, 2013    Key Record Dates
Last Update Posted: October 29, 2019
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Quinidine
Dextromethorphan
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Anti-Arrhythmia Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents